ArriVent BioPharma, Inc. (AVBP) stock
Close on Nov 12, 2026Market cap $644.45MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $644.45M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.64
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$169.07M
- EPS, diluted
- -$3.65
- Book value per share
- $7.94
- Diluted shares
- 50M
Trading
- Next earnings
- Mar 4, 2027 (estimated, after the close)
- Previous close
- $13.51
- Open
- $13.55
- Day's range
- $12.89 – $13.62
- Volume
- 793,949
- Average volume (20 days)
- 1,468,157
- Index membership
- Russell 2000 (since Mar 2024), Russell 3000 (since May 2024)
- Beta (5 years)
- 1.00
- 52-week range
- $11.36 – $35.83
- RSI (14 days)
- 34.3
- Volatility (1 year)
- 81.5%
- Relative volume
- 0.75×
- WACC
- 9.9%
On 2 of our idea lists: More cash than they're worth, Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | AVBP | S&P 500 | Difference | AVBP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -20.6% | -2.7% | −17.9 pts | ||
| 3 months | -58.5% | -1.7% | −56.7 pts | ||
| Year to date | -35.0% | +11.9% | −46.9 pts | ||
| 1 year | -35.3% | +12.0% | −47.3 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases ArriVent BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Results
About ArriVent BioPharma
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical company that identifies, develops, and commercializes differentiated cancer therapies, with a primary focus on solid tumors. Its lead product candidate is firmonertinib, an investigational tyrosine kinase inhibitor evaluated in clinical trials for non-small cell lung cancer characterized by epidermal growth factor receptor mutations, notably exon 20 insertions and PACC mutations. In addition, the firm is developing a pipeline of novel therapeutics, including next-generation antibody drug conjugates such as ARR-217 for gastrointestinal cancers and other solid tumors. Its prospective customers and end users are cancer patients with underserved oncological conditions.
Company profile, executives and historyArriVent BioPharma stock: common questions
What is ArriVent BioPharma's stock price?
AVBP closed at $13.07 on Nov 12, 2026, down 3.22% on the day. Over the past 52 weeks it traded between $11.36 and $35.83.
What is ArriVent BioPharma's market cap?
ArriVent BioPharma was worth $644.45M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is AVBP's P/E ratio?
ArriVent BioPharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.65), so it has no meaningful P/E ratio.
Does ArriVent BioPharma pay a dividend?
No. ArriVent BioPharma has not paid a cash dividend over the last twelve months.
When does ArriVent BioPharma report earnings next?
ArriVent BioPharma is expected to report Q4 FY2026 results on Mar 4, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has AVBP stock performed over the past year?
Including dividends, AVBP returned -35.3% over the past year, against +12.0% for the S&P 500.
How many AVBP shares are sold short?
6M shares were sold short at the latest FINRA report, 12.86% of the float, or 3.4 days of average trading volume.
Who are ArriVent BioPharma's competitors?
Companies most similar to ArriVent BioPharma by business, industry and size include SMMT, NUVB, CBIO, SLS, IMNM.
See a number that looks wrong?